All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Inclacumab
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2020
Details:
In vitro study results demonstrated that inclacumab has the potential to be a best-in-class P-selectin inhibitor for reducing the frequency of VOCs in patients with SCD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TSHA-103
Therapeutic Area: Genetic Disease Product Name: TSHA-103
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
TSHA-103 is an AAV-9-based gene therapy in development for SLC6A1-related epilepsy. TSHA-103 joins portfolio of rare pediatric disease and orphan drug designated product candidates including TSHA-101, TSHA-102 , TSHA-104 and TSHA-118.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABX-002
Therapeutic Area: Genetic Disease Product Name: ABX-002
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Autobahn has gained alignment with FDA on the initial Phase 1a/b clinical trial protocol for ABX-002 as a monotherapy treatment for a rare neurological disorder, adrenomyeloneuropathy (AMN).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PLX-300
Therapeutic Area: Genetic Disease Product Name: PLX-300
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2020
Details:
PLX-300 is a novel, small molecule found in many plants as a deaminated product of phenylalanine. If a new drug application (NDA) for PLX-300 is approved, the Company is eligible to receive a priority review voucher that may be sold or transferred to others.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tissue non-specific alkaline phosphatase
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Soft Bones
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding November 19, 2020
Details:
Grant to support a study looking to determine the efficacy of viral vector delivery of mineral-targeted tissue non-specific alkaline phosphatase (TNAP) to treat late onset or adult HPP.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MMA-101,ImmTOR
Therapeutic Area: Genetic Disease Product Name: MMA-101
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
MMA-101 is an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia due to methylmalonyl-CoA mutase gene mutations. AskBio and Selecta expect to start a Phase 1 trial of MMA-101 and ImmTOR for patients with MMA in the first half of 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AVR-RD-06
Therapeutic Area: Genetic Disease Product Name: AVR-RD-06
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
Positive clinical data out as far as 3.5 years across a broad lysosomal disorder gene therapy pipeline were presented showcasing AVR-RD-02 for Gaucher disease type 1, AVR-RD-01 for Fabry disease, AVR-RD-04 for cystinosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Taurursodiol,Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: AMX0035
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
AMX0035 is designed to target the ER stress, and preclinical data suggest that it may be a promising approach to halt the irreversible progression of optic nerve atrophy in patients with Wolfram syndrome.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
